Herbalife Nutrition Ltd vs Relay Therapeutics Inc. Common Stock — how do they compare? Herbalife Nutrition Ltd trades at $13.03 (market cap $1.34B), while Relay Therapeutics Inc. Common Stock trades at $17.88 (market cap $3.82B). The key difference: Relay Therapeutics Inc. Common Stock is far larger — about 2.9× Herbalife Nutrition Ltd's market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, Herbalife Nutrition Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Herbalife Nutrition Ltd for 43 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| HLF | RLAY | |
|---|---|---|
Market Cap | $1.34B | $3.82B |
Volume | 1,589,457 | 4,332,079 |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $20.75 |
52-Week Low | $7.75 | $6.03 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $3.18B | $2.93B |
Signals from Pluang's Aura AI — not financial advice
HLF trades at $12.82, up 1.34% today, with a bullish technical signal from moving averages and oscillators. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026. Revenue has been stable around $5.0B annually, with a net income margin of 4.53% in 2025. Recent news includes a $250 million share repurchase program and a planned CEO transition effective October 31, 2026.
The stock appears undervalued with a P/E of 8.22 and P/S of 0.26, supported by a 53.84% analyst buy rating and a $19.00 consensus price target. Key risks include high debt levels, with total liabilities at $3.53B, and inconsistent earnings performance. Positive cash flow trends in 2026 projections and margin expansion plans offer potential upside, but investor caution is warranted due to ongoing leadership changes and competitive pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →